News 25.03.2019 SCHLIEREN / ZURICH, SWITZERLAND – March 21, 2019 – Neurimmune today informed that Biogen and Eisai decided to discontinue Phase 3 ENGAGE and EMERGE trials of Aducanumab in Alzheimer’s disease. Neurimmune has partnered Aducanumab with Biogen in 2007. The independent data monitoring committee advised that the trials were unlikely to...
Internal events
Event date: 09.04.2019
If you like to get a 30 minutes IP coaching from Ute-Christine Konopka from thinksafe, you have to think about the challenges you have with IP in your own business. If you have decided to go the „non-IP“ path, even then you have to be aware of some traps you can...
Internal events
Event date: 16.04.2019
Zeit: 17:00 – 17:45, anschliessend Fragen & Antworten
Ort: Auditorium Wagistrasse 25
Themen:
NDA: Einseitig/Zweiseitig, Umfang, Überbindungspflicht, Vertragsdauer, Konventionalstrafe, Gerichtsstand/anwendbares Recht.
Supply Agreement: Produkteänderungen, Preisklauseln, Preisänderungen, Lieferpflicht, Gewährleistung, Haftung
Vertriebsverträge: Exklusivität, Abnahmepflichten/Minimalvolumen, Marketingaktivität, After-Sales, IP
Master Service Agreement: konkrete Resultate, persönliche Ausführung, IP in Bezug auf Resultate, Haftung
Referent: Dr. Michael Tschudin
Michael Tschudin...
News 13.03.2019 Schlieren (Zurich), Switzerland, March 13, 2019 – Kuros Biosciences (SIX: KURN) today announced that its Dutch subsidiary, Kuros Biosciences BV, has received clearance for the Kuros TLIF cage from the U.S. Food and Drug Administration (FDA). The TLIF cage has been developed for the use with KUR-113, Kuros’s advanced Fibrin-PTH product candidate...
News 04.03.2019 ZURICH, Switzerland, March 04, 2019 – NovaGo Therapeutics AG, a Swiss biotech company developing human antibody therapeutics to promote regeneration after cerebral stroke, has closed a Series A financing round of CHF 10 million led by Pureos Bioventures and the strategic partner Neurimmune. Dr. Dominik Escher, Partner at Pureos Bioventures...